Heartflow
Company Snapshot
Heartflow is a medical technology company that has developed an AI-powered platform for the non-invasive diagnosis and management of coronary artery disease (CAD). The company's Heartflow Platform uses advanced computational fluid dynamics to create personalized 3D models of patients' hearts from coronary computed tomography angiography (CCTA) scans. This innovative approach provides actionable insights on blood flow and plaque characteristics, addressing the limitations of traditional imaging tests. Heartflow aims to enhance clinical workflows and improve patient outcomes in the management of CAD.
Key Financials
| Metric | 2024 | 2023 | 2022 |
|---|---|---|---|
| Revenue | $125.8M | $87.2M | Not provided |
| YoY Growth | +44.3% | - | - |
| Adjusted Net Loss | -$96.4M | -$95.7M | Not provided |
| Margin % | -76.6% | -109.7% | - |
S-1 Highlights
Market & Competition
Heartflow operates in the medical technology market focused on cardiovascular disease and competes with established players like Siemens Healthineers, GE Healthcare, and Philips. The company addresses a significant need for accurate and efficient CAD diagnosis and management in a market characterized by high demand for innovative healthcare solutions.
Use of Proceeds
Heartflow plans to use the proceeds from the IPO to invest in research and development, expand its sales and marketing efforts, and enhance its operational capabilities to support growth.
Key Risk Factors
- ●The company faces significant competition from other medical technology firms, which may impact its market share and profitability.
- ●If Heartflow fails to maintain regulatory compliance or faces delays in obtaining necessary approvals, it could adversely affect its business operations and financial performance.
Reported Broker Availability
Reported by users or publicly disclosed. Information is for reference only.